Table. 11.

Number (%) of participants in the proficiency tests for the direct antiglobulin test

Trial Antiglobulin Specimen No. Negative Positive Intended response
1st Polyspecific BBG-21-04 289 289 (100.0) 0 Negative
BBG-21-05 289 289 (100.0) 0 Negative
BBG-21-06 289 0 289 (100.0) Positive
Anti-IgG BBG-21-04 71 71 (100.0) 0 Negative
BBG-21-05 71 71 (100.0) 0 Negative
BBG-21-06 71 0 71 (100.0) Positive
Anti-C3d BBG-21-04 70 70 (100.0) 0 Negative
BBG-21-05 70 70 (100.0) 0 Negative
BBG-21-06 70 70 (100.0) 0 Negative
2nd Polyspecific BBG-21-10 290 289 (99.7) 1 (0.3) Negative
BBG-21-11 290 0 290 (100.0) Positive
BBG-21-12 290 288 (99.3) 2 (0.7) Negative
Anti-IgG BBG-21-10 71 71 (100.0) 0 Negative
BBG-21-11 71 0 71 (100.0) Positive
BBG-21-12 71 71 (100.0) 0 Negative
Anti-C3d BBG-21-10 69 69 (100.0) 0 Negative
BBG-21-11 69 69 (100.0) 0 Negative
BBG-21-12 69 69 (100.0) 0 Negative

Abbreviation: IgG, Immunoglobulin G.

Lab Med Qual Assur 2022;44:10~20 https://doi.org/10.15263/jlmqa.2022.44.1.10
© Lab Med Qual Assur